Literature DB >> 19193159

Additivity in the analysis and design of HIV protease inhibitors.

Robert N Jorissen1, G S Kiran Kumar Reddy, Akbar Ali, Michael D Altman, Sripriya Chellappan, Saima G Anjum, Bruce Tidor, Celia A Schiffer, Tariq M Rana, Michael K Gilson.   

Abstract

We explore the applicability of an additive treatment of substituent effects to the analysis and design of HIV protease inhibitors. Affinity data for a set of inhibitors with a common chemical framework were analyzed to provide estimates of the free energy contribution of each chemical substituent. These estimates were then used to design new inhibitors whose high affinities were confirmed by synthesis and experimental testing. Derivations of additive models by least-squares and ridge-regression methods were found to yield statistically similar results. The additivity approach was also compared with standard molecular descriptor-based QSAR; the latter was not found to provide superior predictions. Crystallographic studies of HIV protease-inhibitor complexes help explain the perhaps surprisingly high degree of substituent additivity in this system, and allow some of the additivity coefficients to be rationalized on a structural basis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19193159      PMCID: PMC2715819          DOI: 10.1021/jm8009525

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  18 in total

1.  Quantitative structure-activity relationship modeling of dopamine D(1) antagonists using comparative molecular field analysis, genetic algorithms-partial least-squares, and K nearest neighbor methods.

Authors:  B Hoffman; S J Cho; W Zheng; S Wyrick; D E Nichols; R B Mailman; A Tropsha
Journal:  J Med Chem       Date:  1999-08-26       Impact factor: 7.446

2.  Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.

Authors:  Dominique L N G Surleraux; Abdellah Tahri; Wim G Verschueren; Geert M E Pille; Herman A de Kock; Tim H M Jonckers; Anik Peeters; Sandra De Meyer; Hilde Azijn; Rudi Pauwels; Marie-Pierre de Bethune; Nancy M King; Moses Prabu-Jeyabalan; Celia A Schiffer; Piet B T P Wigerinck
Journal:  J Med Chem       Date:  2005-03-24       Impact factor: 7.446

3.  Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.

Authors:  John F Miller; C Webster Andrews; Michael Brieger; Eric S Furfine; Michael R Hale; Mary H Hanlon; Richard J Hazen; Istvan Kaldor; Ed W McLean; David Reynolds; Douglas M Sammond; Andrew Spaltenstein; Roger Tung; Elizabeth M Turner; Robert X Xu; Ronald G Sherrill
Journal:  Bioorg Med Chem Lett       Date:  2006-02-03       Impact factor: 2.823

4.  Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesis.

Authors:  Sripriya Chellappan; G S Kiran Kumar Reddy; Akbar Ali; Madhavi N L Nalam; Saima Ghafoor Anjum; Hong Cao; Visvaldas Kairys; Miguel X Fernandes; Michael D Altman; Bruce Tidor; Tariq M Rana; Celia A Schiffer; Michael K Gilson
Journal:  Chem Biol Drug Des       Date:  2007-05       Impact factor: 2.817

5.  Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease.

Authors:  Sripriya Chellappan; Visvaldas Kairys; Miguel X Fernandes; Celia Schiffer; Michael K Gilson
Journal:  Proteins       Date:  2007-08-01

6.  HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants.

Authors:  Michael D Altman; Akbar Ali; G S Kiran Kumar Reddy; Madhavi N L Nalam; Saima Ghafoor Anjum; Hong Cao; Sripriya Chellappan; Visvaldas Kairys; Miguel X Fernandes; Michael K Gilson; Celia A Schiffer; Tariq M Rana; Bruce Tidor
Journal:  J Am Chem Soc       Date:  2008-04-16       Impact factor: 15.419

7.  Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer.

Authors:  E D Matayoshi; G T Wang; G A Krafft; J Erickson
Journal:  Science       Date:  1990-02-23       Impact factor: 47.728

8.  Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.

Authors:  Akbar Ali; G S Kiran Kumar Reddy; Hong Cao; Saima Ghafoor Anjum; Madhavi N L Nalam; Celia A Schiffer; Tariq M Rana
Journal:  J Med Chem       Date:  2006-12-14       Impact factor: 7.446

9.  Substrate envelope and drug resistance: crystal structure of RO1 in complex with wild-type human immunodeficiency virus type 1 protease.

Authors:  Moses Prabu-Jeyabalan; Nancy M King; Ellen A Nalivaika; Gabrielle Heilek-Snyder; Nick Cammack; Celia A Schiffer
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

10.  Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres.

Authors:  G S Kiran Kumar Reddy; Akbar Ali; Madhavi N L Nalam; Saima Ghafoor Anjum; Hong Cao; Robin S Nathans; Celia A Schiffer; Tariq M Rana
Journal:  J Med Chem       Date:  2007-08-16       Impact factor: 7.446

View more
  9 in total

1.  Composite multi-parameter ranking of real and virtual compounds for design of MC4R agonists: renaissance of the Free-Wilson methodology.

Authors:  Ingemar Nilsson; Magnus O Polla
Journal:  J Comput Aided Mol Des       Date:  2012-10-02       Impact factor: 3.686

2.  Site-Specific Fragment Identification Guided by Single-Step Free Energy Perturbation Calculations.

Authors:  E Prabhu Raman; Kenno Vanommeslaeghe; Alexander D Mackerell
Journal:  J Chem Theory Comput       Date:  2012-03-26       Impact factor: 6.006

Review 3.  Structure-based methods for predicting target mutation-induced drug resistance and rational drug design to overcome the problem.

Authors:  Ge-Fei Hao; Guang-Fu Yang; Chang-Guo Zhan
Journal:  Drug Discov Today       Date:  2012-07-10       Impact factor: 7.851

4.  Characterization of small molecule binding. I. Accurate identification of strong inhibitors in virtual screening.

Authors:  Bo Ding; Jian Wang; Nan Li; Wei Wang
Journal:  J Chem Inf Model       Date:  2013-01-09       Impact factor: 4.956

Review 5.  Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection.

Authors:  Jian J Tan; Xiao J Cong; Li M Hu; Cun X Wang; Lee Jia; Xing-Jie Liang
Journal:  Drug Discov Today       Date:  2010-01-22       Impact factor: 7.851

6.  Additivity-based design of the strongest possible turkey ovomucoid third domain inhibitors for porcine pancreatic elastase (PPE) and Streptomyces griseus protease B (SGPB).

Authors:  Mohammad A Qasim; Lixia Wang; Sabiha Qasim; Stephen Lu; Wuyuan Lu; Richard Wynn; Zheng-Ping Yi; Michael Laskowski
Journal:  FEBS Lett       Date:  2013-07-23       Impact factor: 4.124

Review 7.  Theory of free energy and entropy in noncovalent binding.

Authors:  Huan-Xiang Zhou; Michael K Gilson
Journal:  Chem Rev       Date:  2009-09       Impact factor: 60.622

8.  Multi-target QSAR modelling in the analysis and design of HIV-HCV co-inhibitors: an in-silico study.

Authors:  Qi Liu; Han Zhou; Lin Liu; Xi Chen; Ruixin Zhu; Zhiwei Cao
Journal:  BMC Bioinformatics       Date:  2011-07-20       Impact factor: 3.169

9.  A combined 3D-QSAR and docking studies for the In-silico prediction of HIV-protease inhibitors.

Authors:  Zaheer Ul-Haq; Saman Usmani; Hina Shamshad; Uzma Mahmood; Sobia Ahsan Halim
Journal:  Chem Cent J       Date:  2013-05-17       Impact factor: 4.215

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.